Whalesbook
Toh hua yun ki MPS Ltd ka Q3 FY2026 ka revenue 2.1% kam hokar ₹182.5 crore ho gaya aur net profit 12.8% gir kar ₹35.5 crore par aa gaya. Iska seedha connection unke American Journal Experts (AJE) unit se hai, jo Research Solutions segment ka hissa hai. AI tools ke chalte is unit par kaafi pressure aa raha hai. Achhi baat yeh hai ki AJE ko hata kar dekhein toh baaki Research Solutions business 6.5% grow hua aur Education Solutions segment bhi 11.3% upar gaya. Corporate Learning mein company ek 'deliberate reset' kar rahi hai, jahan legacy projects kam karke AI-driven, high-value services par focus kiya ja raha hai, isliye wahan revenue 24% se zyada gira hai.
Company ka balance sheet kaafi strong hai, ₹143 crore cash reserves hain December 2025 tak aur debt bahut kam hai. Stock abhi ₹1,657.70 ke aas paas trade kar raha hai, jiska trailing P/E lagbhag 16.35 hai, jo company ke 5-year median se kam hai. Valuation mein yeh discount dikhata hai ki market abhi company ke transition ko lekar thoda uncertain hai.
Ab sabse important move - January 2026 mein company ne $16.5 million mein Unbound Medicine ko acquire kar liya hai. Yeh deal unki platform-led strategy aur recurring revenue model ko boost karne ke liye ek bada step hai. Unbound Medicine ek U.S. based healthcare technology firm hai jo AI clinical decision support aur medical reference tools banati hai institutions ke liye. MPS ka target hai Unbound ke 14% EBITDA margin ko synergy se badha kar FY2027 tak 30% karna. Yeh acquisition MPS ko subscription business ki taraf le jayegi, jo project-based work se alag hai.
Market mein is transition ko lekar thodi clarity ki kami hai. Unbound acquisition strategically acchi hai, lekin iska successful integration aur synergy realization bahut important hoga. Agar competitors jaise RELX (P/E ~23.7-24.1) aur Pearson (P/E ~21.2-21.5) ko dekhein, toh unke multiples higher hain. Iska matlab market ko predictability aur established platforms pasand hain. MPS ka current valuation is wajah se kam ho sakta hai. Company ke paas high return ratios hain (>30% ROE, >40% ROCE) par execution risks abhi bhi hain, khas kar AJE segment ke AI disruption aur Corporate Learning ke reset ko lekar.
Management ka kehna hai ki FY2026 mein earnings per share ₹100 se upar jayega. FY2027 ko ek inflection point mana ja raha hai, jahan Research Solutions stabilize hoga aur Education Solutions apna double-digit growth continue karega. Corporate Learning bhi recover karega aur Unbound Medicine se bhi accha contribution expect hai. Basically, company ek 'multi-engine' growth model build kar rahi hai, bas ab execution par focus karna hai.